Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $103.31 USD
Change Today -2.35 / -2.22%
Volume 6.5M
GILD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Xetra
As of 12:14 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

gilead sciences inc (GILD) Snapshot

Open
$105.30
Previous Close
$105.66
Day High
$105.73
Day Low
$102.73
52 Week High
10/31/14 - $116.83
52 Week Low
05/5/14 - $76.63
Market Cap
153.3B
Average Volume 10 Days
12.5M
EPS TTM
$8.83
Shares Outstanding
1.5B
EX-Date
06/12/15
P/E TM
11.7x
Dividend
$1.72
Dividend Yield
--
Current Stock Chart for GILEAD SCIENCES INC (GILD)

gilead sciences inc (GILD) Details

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific. The company’s products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with Bristol-Myers Squibb Company', Janssen R&D Ireland, and Japan Tobacco Inc. to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.

7,000 Employees
Last Reported Date: 02/25/15
Founded in 1987

gilead sciences inc (GILD) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.6M
President and Chief Operating Officer
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $797.6K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $920.6K
Executive Vice President of Corporate & Medic...
Total Annual Compensation: $814.3K
Compensation as of Fiscal Year 2014.

gilead sciences inc (GILD) Key Developments

Gilead Sciences Announces Encouraging Results from Phase II HCV Studies

Gilead Sciences Inc. has announced encouraging results from several Phase II clinical studies evaluating investigational uses of Harvoni and other Sovaldi -based regimens for the treatment of chronic hepatitis C virus, or HCV, infection in patients with advanced liver disease, including patients with decompensated cirrhosis, fibrosing cholestatic hepatitis C and portal hypertension. Harvoni and Sovaldi are each approved in the US for the treatment of chronic HCV infection. Harvoni is indicated for patients with genotype 1; Sovaldi is used in combination with other agents and its efficacy has been established in patients with genotypes 1-4. In SOLAR-2 (Study GS-US-337-0124, Oral #G02), 328 genotype 1 or 4 HCV patients with decompensated liver disease before liver transplantation or recurrent HCV infection following liver transplantation were randomized to receive either 12 or 24 weeks of Harvoni plus ribavirin (RBV). Ten patients were excluded from the analysis because of transplantation (n=7) or because they were pre-transplantation, but not decompensated (n=3); an additional 27 of these patients have not yet reached post-treatment week 12. Of the 32 genotype 4 patients, 27 (84%) achieved SVR12. Additionally, among patients with compensated and decompensated cirrhosis before and after liver transplantation, virologic response was associated with improvements in Model for End-Stage Liver Disease (MELD) and CPT scores used to stage end-stage liver disease. The most common adverse events were fatigue, anemia, nausea and headache. Overall, six patients discontinued treatment due to adverse events, five of whom had decompensated cirrhosis. Further supporting the safety profile of Harvoni plus RBV among this patient population was data from a pooled safety analysis of 659 patients treated in the SOLAR-1 and SOLAR-2 studies. Both studies evaluated Harvoni plus RBV for 12 or 24 weeks in genotype 1 or 4 HCV patients with decompensated liver disease or recurrent HCV infection following liver transplantation. SOLAR-1 was conducted in the US, with data presented in November at The Liver Meeting 2014 and SOLAR-2 was conducted in Australia, Canada, Europe and New Zealand. Overall, adverse events were similar to those seen in previous studies, including the Phase III ION studies. Fewer than 3% (n=19/659) of patients discontinued due to an adverse event, none of which were attributed to Harvoni treatment. There were a total of 20 deaths in these two studies, none of which was assessed by the investigator as related to study treatment.

Gilead Sciences Seeks Acquisitions

Gilead Sciences Inc. (NasdaqGS:GILD) is looking for acquisition. Robin Washington, Chief Financial Officer of Gilead Sciences states, "Gilead does keep an eye out for M&A opportunities, prefers phase-two or earlier-stage assets."

Gilead Sciences Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Revises Earnings Guidance for the Full Year of Fiscal 2015

Gilead Sciences Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company announced total revenues of $7,594 million compared to $4,999 million for the same period a year ago. Income from operations was $5,371 million compared to $3,043 million for the same period a year ago. Income before provision for income taxes was $5,239 million compared to $2,949 million for the same period a year ago. Net income was $4,332 million compared to $2,223 million for the same period a year ago. Net income attributable to the company was $4,333 million compared to $2,227 million for the same period a year ago. Net income per share attributable to the company common stockholders – diluted was $2.76 compared to $1.33 for the same period a year ago. Non-GAAP net income attributable to the company was $4,604 million compared to $2,488 million for the same period a year ago. Non-GAAP diluted earnings per share were $2.94 compared to $1.48 for the same period a year ago. The company revised earnings guidance for the full year of fiscal 2015. For the year, the company currently expects to report net product sales between $28,000 million and $29,000 million compared to previous guidance of $26,000 million to $27,000 million. Non-GAAP product gross margin expected to be between 87% and 90% same as previous guidance. The company also expects effective tax rate to be between 18.0% and 20.0% same as previous guidance.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GILD:US $103.26 USD -2.40

GILD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $160.70 USD -1.41
AstraZeneca PLC 4,439 GBp -22.50
GlaxoSmithKline PLC 1,501 GBp -11.00
Merck & Co Inc $60.52 USD -0.12
Sanofi €90.04 EUR -2.25
View Industry Companies
 

Industry Analysis

GILD

Industry Average

Valuation GILD Industry Range
Price/Earnings 12.0x
Price/Sales 5.7x
Price/Book 8.8x
Price/Cash Flow 11.0x
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GILEAD SCIENCES INC, please visit www.gilead.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.